Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia annua pollen skin prick solution is a diagnostic allergen extract developed by Zhejiang Wolwo Bio-Pharmaceutical for the identification of sensitization to sweet wormwood (*Artemisia annua*) pollen. It is used in skin prick testing, a common diagnostic procedure for allergic diseases such as allergic rhinitis and allergic conjunctivitis. When applied percutaneously, the solution introduces pollen allergens into the skin; in individuals with specific IgE antibodies to these allergens, the extract cross-links IgE on the surface of mast cells, triggering degranulation and the release of inflammatory mediators. This results in a localized wheal-and-flare reaction, the size of which indicates the degree of sensitization. The product has been evaluated in Phase III clinical trials in China (e.g., CTR20200810) to establish its safety and diagnostic performance (sensitivity and specificity) alongside other common allergen extracts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia annua pollen skin prick solution.